MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Kodu・Aktsiate loetelu・SCYNEXIS Inc

SCYNEXIS Inc

Suletud

0.61 1.67

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.58

Max

0.62

Põhinäitajad
By Trading Economics
Sissetulek	-1.7M -8.6M
Müük	-1M 334K
Kasumimarginaal	-2,572.156
Töötajad	28
EBITDA	9.4M -186K

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+455.56% upside

Turustatistika
By TradingEconomics
Turukapital	-612K 26M
Eelmine avamishind	-1.06
Eelmine sulgemishind	0.61

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

0.9307 / 0.9907 Toetus ja vastupanu

SCYNEXIS Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. dets 2025, 22:20 UTC

Suurimad hinnamuutused turgudel

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31. dets 2025, 17:31 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31. dets 2025, 16:30 UTC

Suurimad hinnamuutused turgudel

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31. dets 2025, 15:19 UTC

Suurimad hinnamuutused turgudel

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31. dets 2025, 15:17 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31. dets 2025, 14:37 UTC

Suurimad hinnamuutused turgudel

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. dets 2025, 21:13 UTC

Omandamised, ülevõtmised, äriostud

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31. dets 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31. dets 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31. dets 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31. dets 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31. dets 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31. dets 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31. dets 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31. dets 2025, 17:16 UTC

Suurimad hinnamuutused turgudel

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31. dets 2025, 17:00 UTC

Omandamised, ülevõtmised, äriostud

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31. dets 2025, 15:57 UTC

Omandamised, ülevõtmised, äriostud

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31. dets 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31. dets 2025, 15:02 UTC

Suurimad hinnamuutused turgudel

Nike Shares Rise After CEO Hill Buys $1M of Shares

31. dets 2025, 14:40 UTC

Omandamised, ülevõtmised, äriostud

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31. dets 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31. dets 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31. dets 2025, 13:01 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31. dets 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

31. dets 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

31. dets 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31. dets 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31. dets 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Võrdlus sarnastega

Hinnamuutus

SCYNEXIS Inc Prognoos

Hinnasiht

By TipRanks

455.56% tõus

12 kuu keskmine prognoos

Keskmine 3.5 USD 455.56%

Kõrge 4 USD

Madal 3 USD

Põhineb 2 Wall Streeti analüütiku instrumendi SCYNEXIS Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi SCYNEXIS Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9307 / 0.9907Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.